Transcriptome profile of hepatocellular carcinoma in patients with atezolizumab plus bevacizumab therapy.

Hepatocellular carcinoma (HCC) is a rapidly increasing and highly lethal cancer worldwide, with many patients diagnosed at advanced stages and early-stage patients often experiencing high recurrence rates. The combination of atezolizumab plus bevacizumab emerged as a groundbreaking immunotherapy, establishing a new standard of care for advanced HCC. There's an urgent need for reliable biomarkers to predict patient responses and personalize treatment. We collected tumor samples from advanced HCC patients wirth atezolizumab plus bevacizumab therapy and performed comprehensive analyses of the tumor microenvironment using bulk RNA sequencing to identify key features influencing the effectiveness of atezolizumab plus bevacizumab. Overall design: HCC tumor tissues were obtained from a total of 73 patients who underwent diagnostic liver biopsy and used for RNA isolation and genome-wide transcriptome profiling by bulk RNA sequencing.